Authors:
Spooner, RA
Maycroft, KA
Paterson, H
Friedlos, F
Springer, CJ
Marais, R
Citation: Ra. Spooner et al., Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy, INT J CANC, 93(1), 2001, pp. 123-130
Authors:
Stribbling, SM
Friedlos, F
Martin, J
Davies, L
Spooner, RA
Marais, R
Springer, CJ
Citation: Sm. Stribbling et al., Regressions of established breast carcinoma xenografts by carboxypeptidaseG2 suicide gene therapy and the prodrug CMDA are due to a bystander effect, HUM GENE TH, 11(2), 2000, pp. 285-292
Authors:
Spooner, RA
Martin, J
Friedlos, F
Marais, R
Springer, CJ
Citation: Ra. Spooner et al., In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug, CANC GENE T, 7(10), 2000, pp. 1348-1356
Citation: Cj. Springer et I. Niculescu-duvaz, Patent property of suicide gene therapy involving prodrugs 1996-1999, EXPERT OP T, 9(10), 1999, pp. 1381-1388
Authors:
Niculescu-Duvaz, I
Friedlos, F
Niculescu-Duvaz, D
Davies, L
Springer, CJ
Citation: I. Niculescu-duvaz et al., Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT), ANTI-CAN DR, 14(6), 1999, pp. 517-538
Authors:
Pedley, RB
Sharma, SK
Boxer, GM
Boden, R
Stribbling, SM
Davies, L
Springer, CJ
Begent, RHJ
Citation: Rb. Pedley et al., Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent, CANCER RES, 59(16), 1999, pp. 3998-4003